[Use of antihypoxants in the acute period of myocardial infarction].
A total of 620 patients with acute myocardial infarction were followed up in order to assess the efficacy of antihypoxants as a component of intensive care. 385 of these patients, divided into groups of 20-40 subjects, were administered one of 12 antihypoxants or sessions of hyperbaric oxygenation during the acute period of the disease, the rest were treated traditionally. Analysis of clinical, laboratory, and prognostic values showed the highest protective effect of amtizol, lithium hydroxybutyrate, piracetam, and ubiquinone. Cytochrome C, riboxine, mildronate, and olifen were somewhat less active, and solcoseryl, bemitil, trimethasidine, and aspisol were the least effective. The protective potentialities of standard sessions of hyperbaric oxygenation were virtually null. The author proposes a parameter D, reflecting the difference between actual and predicted mortality, and the rating (score) system for assessing the routine laboratory diagnostic tests to be used together with the known criteria for evaluation of the protective effects of antihypoxants in patients with acute myocardial infarction.
Semigolovskiĭ
N Iu
NIu
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D001241:Aspirin / Q000031:analogs & derivatives / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003574:Cytochrome c Group / Q000627:therapeutic use; D006801:Humans; D006885:Hydroxybutyrates / Q000627:therapeutic use; D006931:Hyperbaric Oxygenation; D007288:Inosine / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D008239:Lysine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008763:Methylhydrazines / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy*; D018697:Nootropic Agents / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010647:Phenyl Ethers / Q000627:therapeutic use; D010889:Piracetam / Q000627:therapeutic use; D013830:Thiadiazoles / Q000627:therapeutic use; D014292:Trimetazidine / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D001562:Benzimidazoles; D002317:Cardiovascular Agents; D003574:Cytochrome c Group; D006885:Hydroxybutyrates; D008763:Methylhydrazines; D018697:Nootropic Agents; D009942:Organometallic Compounds; D010647:Phenyl Ethers; D013830:Thiadiazoles; D014665:Vasodilator Agents; C085806:olifen; C044365:amtizol; D007288:Inosine; C022826:lithium hydroxybutyrate; C049825:bemethyl; C050147:3-(2,2,2-trimethylhydrazine)propionate; D008094:Lithium; D008239:Lysine; D014292:Trimetazidine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate; D010889:Piracetam
Primenenie antigipoksantov v ostrom periode infarkta miokarda.